Biotech spin-off targets fibrosis, neoplasm and neovascularization

Aspire-FTD study aims to stop disease progression with one-time treatment

Trial progresses towards topline data expected later in the year

FDA recognises KER-0193 as a potential therapy for rare paediatric disease

Screening begins for study evaluating LTI-03 in idiopathic pulmonary fibrosi

Private equity firm Apiary Capital backs rapid growth of performance-i

Teprotumumab approved as first targeted treatment for thyroid eye disease

Study explores whether PI3Kδ targeting could combat resistance

UCB’s developmental treatment may be eligible for patient access